Amylyx Pharmaceuticals, INC Form 4 insider transactions

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc., sold 30,000 shares of common stock on July 9, 2026.

Bernhardt G. Zeiher, a Director at Amylyx Pharmaceuticals, Inc., acquired 24,372 stock options on June 4, 2026, with an exercise price of $14.31.

Karen Firestone, a Director at Amylyx Pharmaceuticals, acquired 24,372 stock options with an exercise price of $14.31.

Daphne Quimi, a Director at Amylyx Pharmaceuticals, acquired 24,372 stock options with an exercise price of $14.31 on June 4, 2026.

Amylyx Pharmaceuticals reports a Form 4 filing detailing the acquisition of stock options by Director George M. Milne Jr.

Paul R. Fonteyne, a Director at Amylyx Pharmaceuticals, acquired stock options for 24,372 shares.

Amylyx Pharmaceuticals Director Karen Firestone reported a transaction involving the acquisition of 3,800 shares of common stock.

Amylyx Pharmaceuticals' Co-CEO, Justin B. Klee, sold 29,282 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals' Co-Chief Executive Officer, Joshua B. Cohen, sold 29,282 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals' Chief Medical Officer, Camille L. Bedrosian, sold 6,461 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals' CFO, James M. Frates, has filed a plan to sell 7,909 shares of common stock on March 2, 2026, to cover tax withholding obligations.

Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold 6,844 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold 3,419 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen exercised stock options and subsequently sold shares to cover costs and tax obligations, as per a pre-arranged 10b5-1 plan.

Amylyx Pharmaceuticals Co-CEO Justin Klee exercised stock options and subsequently sold a portion of the acquired shares to cover costs and tax obligations.

Amylyx Pharmaceuticals Director George M. Milne Jr. gifted 17,780 shares of common stock on January 12, 2026.

Amylyx Pharmaceuticals CFO James M. Frates reported the sale of 3,326 common shares for tax obligations and the contribution of 100,000 shares to a grantor retained annuity trust.

Amylyx Pharmaceuticals Co-CEO Joshua B. Cohen sold 7,715 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals Co-CEO Justin B. Klee sold 7,715 shares of common stock at a weighted average price of $11.0939 to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals Director Karen Firestone acquired 8,100 shares of common stock for approximately $100,845, signaling confidence in the company.

Amylyx Pharmaceuticals' Chief Medical Officer, Camille L. Bedrosian, sold 6,580 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals Co-CEO Joshua B. Cohen sold 29,933 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals' Chief Medical Officer, Camille L. Bedrosian, sold 12,039 shares of common stock to cover tax withholding obligations.

Amylyx Pharmaceuticals Co-CEO Justin B. Klee sold 29,975 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold 8,828 shares of common stock at a weighted average price of $14.5751 to cover tax withholding obligations.

Amylyx Pharmaceuticals CFO James M. Frates sold 10,558 shares of common stock on September 30, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold 30,000 shares of common stock in August 2025 under a pre-arranged trading plan.

Amylyx Pharmaceuticals, Inc. Director Bernhardt G. Zeiher was granted 25,000 stock options with an exercise price of $5.05, vesting over approximately one year.

Paul R. Fonteyne, a Director at Amylyx Pharmaceuticals, Inc. (AMLX), has acquired 25,000 stock options with an exercise price of $5.05, set to vest by June 2026.

Amylyx Pharmaceuticals Director Karen Firestone was granted 25,000 stock options with an exercise price of $5.05, vesting by June 2026 or the next annual meeting.